Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Shield Therapeutics Plc
November 2024 Investor Forum
21st Nov 2024
Custodian Property Income REIT plc
November 2024 Investor Forum
20th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
105: Finding the venture opportunity in the energy transition | Reuben Wilcock of Blackfinch Ventures
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
Allergy Therapeutics plc
Life Sciences
Trading update: gaining market share
17 Jan 2019
Diurnal Group Plc
Life Sciences
Chronocort – seeking regulatory advice
15 Jan 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences
Hardman & Co Healthcare Index
By
Dr Martin Hall
11 Jan 2019
Tissue Regenix
Life Sciences
2018 in review: foundations laid for osteobiologics
17 Dec 2018
genedrive Plc
Life Sciences
Accelerating into fiscal 2019 with first sales
10 Dec 2018
Avacta Group plc
Life Sciences
Wake-up call for the market
10 Dec 2018
Redx Pharma
Life Sciences
RXC006: first anti-fibrosis development candidate
By
Dr Martin Hall
30 Nov 2018
Redx Pharma
Life Sciences
Streamlined, focused and good value
27 Nov 2018
Chronix Biomedical
Life Sciences
Monitoring treatment, improving outcomes
13 Nov 2018
Redx Pharma
Life Sciences
ROCK2 inhibitors in chronic kidney disease
09 Nov 2018
Alliance Pharma Plc
Life Sciences
International brands driving performance
07 Nov 2018
Prev
1
...
10
11
12
13
14
...
22
Next
